The receptor binding domain of the new Middle East respiratory syndrome coronavirus maps to a 231-residue region in the spike protein that efficiently elicits neutralizing antibodies.
about
State of Knowledge and Data Gaps of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in HumansReceptor-binding domain-based subunit vaccines against MERS-CoVCurrent advancements and potential strategies in the development of MERS-CoV vaccinesCrystal Structure of the Receptor-Binding Domain from Newly Emerged Middle East Respiratory Syndrome CoronavirusStructure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitorCoronaviruses and the human airway: a universal system for virus-host interaction studiesA review of treatment modalities for Middle East Respiratory Syndrome.Feasibility of Using Convalescent Plasma Immunotherapy for MERS-CoV Infection, Saudi Arabia.Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: Implication for designing novel mucosal MERS vaccines.Tailoring subunit vaccine immunity with adjuvant combinations and delivery routes using the Middle East respiratory coronavirus (MERS-CoV) receptor-binding domain as an antigen.Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus.A Highly Immunogenic and Protective Middle East Respiratory Syndrome Coronavirus Vaccine Based on a Recombinant Measles Virus Vaccine Platform.Epitope-Based Vaccine Target Screening against Highly Pathogenic MERS-CoV: An In Silico Approach Applied to Emerging Infectious Diseases.Pre-fusion structure of a human coronavirus spike protein.Receptor-binding domain of MERS-CoV with optimal immunogen dosage and immunization interval protects human transgenic mice from MERS-CoV infection.A novel neutralizing monoclonal antibody targeting the N-terminal domain of the MERS-CoV spike proteinIdentification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution.Structure, Function, and Evolution of Coronavirus Spike Proteins.The emergence of the Middle East respiratory syndrome coronavirusHost species restriction of Middle East respiratory syndrome coronavirus through its receptor, dipeptidyl peptidase 4.Receptor usage and cell entry of bat coronavirus HKU4 provide insight into bat-to-human transmission of MERS coronavirus.Searching for an ideal vaccine candidate among different MERS coronavirus receptor-binding fragments--the importance of immunofocusing in subunit vaccine design.Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like diseaseThe amino acids 736-761 of the MERS-CoV spike protein induce neutralizing antibodies: implications for the development of vaccines and antiviral agents.Development of human neutralizing monoclonal antibodies for prevention and therapy of MERS-CoV infectionsA truncated receptor-binding domain of MERS-CoV spike protein potently inhibits MERS-CoV infection and induces strong neutralizing antibody responses: implication for developing therapeutics and vaccinesReceptor recognition mechanisms of coronaviruses: a decade of structural studies.Potent neutralization of MERS-CoV by human neutralizing monoclonal antibodies to the viral spike glycoprotein.Optimization of antigen dose for a receptor-binding domain-based subunit vaccine against MERS coronavirus.Identification of the Receptor-Binding Domain of the Spike Glycoprotein of Human Betacoronavirus HKU1.Evaluation of candidate vaccine approaches for MERS-CoV.Structural basis for the neutralization of MERS-CoV by a human monoclonal antibody MERS-27A synthetic consensus anti-spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates.Recombinant Receptor Binding Domain Protein Induces Partial Protective Immunity in Rhesus Macaques Against Middle East Respiratory Syndrome Coronavirus Challenge.Protective Effect of Intranasal Regimens Containing Peptidic Middle East Respiratory Syndrome Coronavirus Fusion Inhibitor Against MERS-CoV InfectionTreatment strategies for Middle East respiratory syndrome coronavirus.A safe and convenient pseudovirus-based inhibition assay to detect neutralizing antibodies and screen for viral entry inhibitors against the novel human coronavirus MERS-CoVEngineering a replication-competent, propagation-defective Middle East respiratory syndrome coronavirus as a vaccine candidateCell-based antiviral screening against coronaviruses: developing virus-specific and broad-spectrum inhibitorsPreventative Vaccines for Zika Virus Outbreak: Preliminary Evaluation.
P2860
Q21128649-83865900-2113-48C1-AFB7-489C5C872268Q26851979-D2121341-2B5C-4B93-8A0F-CDFF7CF8FA6AQ27012578-9C47741D-1ED0-4051-871B-18DC8A3A0D5AQ27679307-A8674912-ED63-490B-A7EE-8217EDED018CQ27689029-3F6D8A26-5B5B-43A4-B552-A50052CA3CFFQ28075580-9868C4D8-17AF-44AC-B695-EDB809431963Q30248209-F71B7E22-1D56-4BE9-85FB-97933A888CFFQ30356651-8CB66616-87B0-439A-861B-3AD264DD527EQ30359335-8055D463-CD28-4273-B860-EA62EE07BD8AQ30368736-82C2B5A4-E6E2-4FD6-B699-B5AF60B076B3Q30371303-E5EEEF05-FC30-40E0-9665-CB16BC667EF6Q30378994-F450F2B6-D18B-40D4-BE05-7CA1CD6BCE40Q30382230-836982FA-3853-4137-8AFC-6DB418572E86Q30385177-54E8B1F1-071F-46C5-8527-C07F5BA46BB5Q30399700-92A42690-BC9C-4117-9D98-617B4F176A2FQ30402347-2A09F167-793B-4515-91A6-CFC8DA6B3E13Q33627189-1C0D00AE-AE67-48D5-A6FB-EFA99975807EQ33760875-AEC81B5B-FF7E-42E7-AE00-657AD24C6392Q33934034-D32B97E5-8028-4E03-AF05-D260E8F47A80Q34059153-F8310B7E-7F58-4F7F-9634-4825AD247A27Q34120263-F21AE2DA-3FB3-444C-B9D7-914C0B5CE254Q34324907-CAFDB2E9-DA0F-4A0D-96A7-EE047AB2673FQ34468689-3CB865F5-31F1-4C66-A946-8F9856908FB5Q34652511-AA4F7B7C-AEAC-4585-91E5-33EFB267F9E4Q35019893-E9C12E47-11A1-4F85-8A56-4D1CE65C9638Q35063993-ED761737-EB60-4A99-B405-F6CEBB395E15Q35115572-6A8D49BD-873C-4613-84C9-38BF6DFBD6E1Q35159147-EA585E17-71BD-4271-9DFA-DEFB2E512F33Q35887626-2E468580-2849-428A-A18D-ABB54A4D93C7Q35913855-91EAC9F7-F69E-4BFA-87F8-F7C9F6503076Q35917397-11B20265-45CB-48FA-9960-BED78AF3005FQ35964208-B2688EC8-D5E8-4FA3-BCA2-FE908AC296DFQ36069589-8F06DA4E-BD26-4D10-887D-F3D6CE600848Q36252666-7EB18BAF-3D40-433E-8DA6-5751EEECC19BQ36306931-01B236B2-3568-4182-8DBA-E5FDBDDA63A4Q36555622-2EA162FB-C5EA-4BFB-B5DD-5FA97BDBDC8DQ37152873-57A4AFD5-C197-4AC9-80F2-60DF87F04EF0Q37174550-B1A2A618-1C99-4DD0-9C66-F5CE60275989Q37596746-54869738-7F43-4891-AC5F-C8FE02E2641FQ37605206-C1DCDAF2-FB82-443C-A19A-B7EF4DF55B1F
P2860
The receptor binding domain of the new Middle East respiratory syndrome coronavirus maps to a 231-residue region in the spike protein that efficiently elicits neutralizing antibodies.
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
The receptor binding domain of ...... icits neutralizing antibodies.
@ast
The receptor binding domain of ...... icits neutralizing antibodies.
@en
The receptor binding domain of ...... icits neutralizing antibodies.
@nl
type
label
The receptor binding domain of ...... icits neutralizing antibodies.
@ast
The receptor binding domain of ...... icits neutralizing antibodies.
@en
The receptor binding domain of ...... icits neutralizing antibodies.
@nl
altLabel
The receptor binding domain of ...... licits neutralizing antibodies
@en
prefLabel
The receptor binding domain of ...... icits neutralizing antibodies.
@ast
The receptor binding domain of ...... icits neutralizing antibodies.
@en
The receptor binding domain of ...... icits neutralizing antibodies.
@nl
P2860
P50
P921
P356
P1433
P1476
The receptor binding domain of ...... icits neutralizing antibodies.
@en
P2093
Huihui Mou
V Stalin Raj
P2860
P304
P356
10.1128/JVI.01277-13
P407
P577
2013-06-19T00:00:00Z